EPIX News and Press, ESSA Pharma Inc. From 12/12/23

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 Canada NewsWire Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety ...

Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...

ESSA Pharma Inc. (EPIX) is expected to report $-0.23 for Q4 2023

2023-11-24 10:41:14 ET More on 3D Systems 3D Systems Corporation (DDD) Q3 2023 Earnings Call Transcript 3D Systems: No Relief In Sight For further details see: ESSA Pharma director Franklin Berger buys common shares worth ~$133.3K

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmac...

2023-11-17 10:41:27 ET More on ESSA Pharma ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance Seeking Alpha’s Quant Rating on ESSA Pharma For further details see: ESSA Pharma says Berger bought 76.5K shares in co

ESSA Pharma to Present at the Jefferies London Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO , Calif. and VANCOUVER, Canada , Nov. 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutica...

2023-11-07 19:06:24 ET Summary A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical conference. EPI-7386 is being advanced as a monot...

2023-11-07 09:23:48 ET More on ESSA Pharma Seeking Alpha’s Quant Rating on ESSA Pharma Historical earnings data for ESSA Pharma Financial information for ESSA Pharma For further details see: ESSA Pharma enters into at-the-market equity offering sal...

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in pat...